BOS172722
- Generic Name
- BOS172722
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30N8O
- CAS Number
- 1578245-44-9
- Unique Ingredient Identifier
- -
- Background
BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent. Normally, Mps1 supports the proper division of cancer cells, ensuring survival and replication. The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favor...
- Associated Conditions
- -
- Associated Therapies
- -
Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT03328494
- Locations
- 🇬🇧
Edinburgh Cancer Centre - Western General Hospital, Edinburgh, United Kingdom
🇬🇧Addenbrooks Hospital, Cambridge, United Kingdom
🇬🇧Royal Marsden, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath